Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.42) by 17.6 percent. This is a 86.18 percent increase over losses of $(14.40) per share from the same period last year. The company reported quarterly sales of $6.733 million which missed the analyst consensus estimate of $6.832 million by 1.45 percent. This is a 13.36 percent decrease over sales of $7.771 million the same period last year.